Q-Line Biotech Limited

<table><tbody><tr><td><strong>Purchases of Raw Material During the year(i+ii)</strong></td><td><strong>6,716.22</strong></td><td><strong>4,998.41</strong></td><td><strong>1,282.45</strong></td></tr><tr><td>Import Purchases (i)</td><td>2,033.13</td><td>1,948.53</td><td>702.53</td></tr><tr><td>Domestic Purchases (ii)</td><td>4,683.09</td><td>3,049.88</td><td>579.92</td></tr><tr><td>Closing stock of Raw Material</td><td>5,147.70</td><td>4,193.53</td><td>829.86</td></tr><tr><td><strong>Total Cost of Material Consumed</strong></td><td><strong>5,762.05</strong></td><td><strong>1,634.74</strong></td><td><strong>908.03</strong></td></tr><tr><td><strong>(B) Purchase of Stock in Trade</strong></td><td></td><td></td><td></td></tr><tr><td>Clinical Chemistry Reagents</td><td>2,147.01</td><td>1,846.32</td><td>1,649.39</td></tr><tr><td>Hematology Analyzer</td><td>2,033.44</td><td>4,098.25</td><td>1,142.43</td></tr><tr><td>Clinical Chemistry Analyzer</td><td>1,025.74</td><td>1,450.66</td><td>1,503.57</td></tr><tr><td>Hematology Reagent</td><td>778.29</td><td>1,178.26</td><td>1,505.13</td></tr><tr><td>Others</td><td>1,696.09</td><td>2,079.70</td><td>2,639.78</td></tr><tr><td><strong>Total Purchases of Stock in Trade</strong></td><td><strong>7,680.57</strong></td><td><strong>10,653.19</strong></td><td><strong>8,440.30</strong></td></tr><tr><td>Less: Contract Acquisition Expenses</td><td>(1,081.87)</td><td>-</td><td>-</td></tr><tr><td>Less: Cost of stock-in trade transferred to Expenses</td><td>(171.09)</td><td>(3.87)</td><td>(44.80)</td></tr><tr><td>Less: Cost of stock-in trade transferred to R&D</td><td>(4.72)</td><td>(24.89)</td><td>-</td></tr><tr><td>Less: Goods used for R&D</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Less: Cost of stock-in trade transferred to Fixed Assets</td><td>(50.14)</td><td>(156.23)</td><td>(8.41)</td></tr><tr><td><strong>Total Net Purchases of Stock in Trade</strong></td><td><strong>6,372.75</strong></td><td><strong>10,468.19</strong></td><td><strong>8,387.09</strong></td></tr><tr><td><strong>Total (A+B)</strong></td><td><strong>12,134.81</strong></td><td><strong>12,102.93</strong></td><td><strong>9,295.12</strong></td></tr></tbody></table>

Notes 1. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, V, I, II and III.

## ANNEXURE – R
### RESTATED CONSOLIDATED STATEMENT OF CHANGES IN INVENTORIES

(Amt. in Lakh Rs.)

<table><thead><tr><th rowspan="2">Particulars</th><th colspan="3">For the Year ended on</th></tr><tr><th>31-03-2025</th><th>31-03-2024</th><th>31-03-2023</th></tr></thead><tbody><tr><td><strong>Closing Inventories</strong></td><td></td><td></td><td></td></tr><tr><td>WIP</td><td>234.54</td><td>351.16</td><td>2.67</td></tr><tr><td>Stock in Trade</td><td>3,169.20</td><td>5,702.28</td><td>3,316.34</td></tr><tr><td>Finished Goods</td><td>494.64</td><td>277.13</td><td>210.57</td></tr><tr><td><strong>Sub Total (A)</strong></td><td><strong>3,898.38</strong></td><td><strong>6,330.57</strong></td><td><strong>3,529.59</strong></td></tr><tr><td><strong>Opening Inventories</strong></td><td></td><td></td><td></td></tr><tr><td>WIP</td><td>351.16</td><td>2.67</td><td>14.84</td></tr><tr><td>Stock in Trade</td><td>5,702.28</td><td>3,316.34</td><td>2,908.42</td></tr><tr><td>Finished Goods</td><td>277.13</td><td>210.57</td><td>157.75</td></tr><tr><td>Less:-Stock t/f to Fixed Assets</td><td>-</td><td>-</td><td>-</td></tr><tr><td><strong>Sub Total (B)</strong></td><td><strong>6,330.57</strong></td><td><strong>3,529.59</strong></td><td><strong>3,081.02</strong></td></tr><tr><td><strong>Changes in Inventories</strong></td><td><strong>2,432.18</strong></td><td><strong>(2,800.98)</strong></td><td><strong>(448.57)</strong></td></tr></tbody></table>

### Notes

1. The above statement should be read with the significant accounting policies and notes to restated statements of assets and liabilities, Statement of profits and losses and Statement of cash flows appearing in Annexures IV, V, I, II and III.

## ANNEXURE – S
### RESTATED CONSOLIDATED STATEMENT OF EMPLOYEE BENEFITS EXPENSES

(Amount in Rs. Lakhs)

<table><thead><tr><th rowspan="2">Particulars</th><th colspan="3">for the Year ended on</th></tr><tr><th>31-03-2025</th><th>31-03-2024</th><th>31-03-2023</th></tr></thead><tbody><tr><td><strong>(A) Salary and Wages</strong></td><td></td><td></td><td></td></tr><tr><td>Director Remuneration</td><td>309.04</td><td>296.90</td><td>480.05</td></tr><tr><td>Employees Salary Expenses</td><td>2,413.35</td><td>1,900.57</td><td>1,806.97</td></tr><tr><td><strong>(B) Contribution to Provident Fund and Other Fund</strong></td><td></td><td></td><td></td></tr></tbody></table>

224